{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:08:14Z","timestamp":1794546494490,"version":"4.9.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1016\/j.ygyno.2005.12.020","type":"journal-article","created":{"date-parts":[[2006,1,27]],"date-time":"2006-01-27T15:34:01Z","timestamp":1138376041000},"page":"300-308","source":"Crossref","is-referenced-by-count":135,"title":["A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel\/platinum containing chemotherapy: A National Cancer Institute of Canada Clinical Trials Group Study"],"prefix":"10.1016","volume":"102","author":[{"given":"H.","family":"Hirte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.B.","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.R.","family":"Jeffrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.N.","family":"Grimshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Coppieters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sadura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Brundage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2005.12.020_bib1","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1136\/bmj.303.6807.884","article-title":"Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials","volume":"303","year":"1991","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ygyno.2005.12.020_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2005.12.020_bib3","first-page":"352a","article-title":"Is cisplatin\u2013paclitaxel (P\u2013T) the standard in the first line treatment of advanced ovarian cancer? The EORTC-GCCG, NOCOVA, NCIC and Scottish Intergroup experience","volume":"16","author":"Piccart","year":"1997","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2005.12.020_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4049\/jimmunol.156.1.1","article-title":"Matrix metalloproteinases in immunity","volume":"156","author":"Goetzl","year":"1996","journal-title":"J. Immunol."},{"key":"10.1016\/j.ygyno.2005.12.020_bib5","first-page":"385","article-title":"Proteinases and inhibitors","volume":"51","author":"Cawston","year":"1995","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ygyno.2005.12.020_bib6","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1749-6632.1994.tb24738.x","article-title":"Matrix metalloproteinases and their inhibitors in tumor progression","volume":"732","author":"De Clerck","year":"1994","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ygyno.2005.12.020_bib7","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/oxfordjournals.annonc.a059091","article-title":"Matrix metalloproteinase inhibition: a review of anti-tumour activity","volume":"6","author":"Brown","year":"1995","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2005.12.020_bib8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/BF03032599","article-title":"The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis","volume":"7","author":"John","year":"2001","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.ygyno.2005.12.020_bib9","first-page":"673","article-title":"Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary","volume":"17","author":"Sakata","year":"2000","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ygyno.2005.12.020_bib10","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1023\/A:1006723011835","article-title":"High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlated with poor survival in ovarian carcinoma","volume":"17","author":"Davidson","year":"1999","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.ygyno.2005.12.020_bib11","first-page":"2396","article-title":"Increased expression of matrix metalloproteinases MMP-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer","volume":"7","author":"Schmalfeldt","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2005.12.020_bib12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0303-7207(01)00709-2","article-title":"The prognostic value of metalloproteinases and angiogenic factors in ovarian cancer","volume":"187","author":"Davidson","year":"2002","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ygyno.2005.12.020_bib13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1749-6632.1994.tb24722.x","article-title":"Regulation of matrix metalloproteinase activity","volume":"732","author":"Murphy","year":"1994","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ygyno.2005.12.020_bib14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1517\/14728214.2.1.205","article-title":"Matrix metalloproteinase inhibiting drugs","volume":"2","author":"Levy","year":"1997","journal-title":"Emerg. Drugs"},{"key":"10.1016\/j.ygyno.2005.12.020_bib15","unstructured":"Kluender H, Dixon B, VanZandt M. et al. Substituted 4-biarylbutyric acid derivatives as matrix metalloproteinase inhibitors. U.S. patent 5,861,428 granted to Bayer Corp. January 19, 1999."},{"key":"10.1016\/j.ygyno.2005.12.020_bib16","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1200\/JCO.2000.18.1.178","article-title":"Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies","volume":"18","author":"Rowinsky","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2005.12.020_bib17","first-page":"213a","article-title":"Phase I and pharmacokinetic study of the matrix metalloproteinase inhibitor (MMPI), BAY 12-9566","volume":"17","author":"Grochow","year":"1998","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2005.12.020_bib18","first-page":"217a","article-title":"Phase I study of BAY 12-9566\u2014a matrix metalloproteinase inhibitor (MMPI)","volume":"17","author":"Erlichman","year":"1998","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2005.12.020_bib19","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1023\/A:1008347630465","article-title":"A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours","volume":"11","author":"Hirte","year":"2000","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2005.12.020_bib20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2005.12.020_bib21","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/1097-0215(200002)9999:9999<::AID-IJC1135>3.0.CO;2-M","article-title":"Quantification of matrix metalloproteinase activity in plasma of patients enrolled in a BAY 12-9566 phase I study","volume":"15","author":"Duivenvoorden","year":"2001","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2005.12.020_bib22","first-page":"240a","article-title":"A comparison between gemcitabine and the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced pancreatic cancer","volume":"19","author":"Moore","year":"2000","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"issue":"Suppl. 2","key":"10.1016\/j.ygyno.2005.12.020_bib23","first-page":"75","article-title":"Preclinical and clinical pharmacology of matrix metalloproteinase inhibitors (MMPIs)","volume":"9","author":"Grochow","year":"1998","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2005.12.020_bib24","first-page":"302","article-title":"Pharmacokinetics and efficacy of a novel matrix metalloproteinase inhibitor AG3340 in single agent and combination therapy against B16\u2013F10 melanoma tumors developing in the lung after IV-tail vein implantation in C57BL\/6 mice","volume":"39","author":"Neri","year":"1998","journal-title":"Proc. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.ygyno.2005.12.020_bib25","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1200\/JCO.1998.16.6.2150","article-title":"Phase I trial of marismastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer","volume":"16","author":"Wojtowicz-Praga","year":"1998","journal-title":"J. Clin. Oncol."},{"issue":"suppl 2","key":"10.1016\/j.ygyno.2005.12.020_bib26","first-page":"74","article-title":"A phase I study of AG3340, a matrix metalloprotease (MMP) inhibitor, in patients having advanced cancer","volume":"9","author":"Hande","year":"1998","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2005.12.020_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.1994.tb24719.x","article-title":"Clinical importance of metalloproteinase and their inhibitors","volume":"732","author":"Krane","year":"1994","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ygyno.2005.12.020_bib28","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1200\/JCO.2001.19.15.3447","article-title":"Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial","volume":"19","author":"Bramhall","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2005.12.020_bib29","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1038\/sj.bjc.6600310","article-title":"Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial","volume":"86","author":"Bramhall","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2005.12.020_bib30","first-page":"11a","article-title":"Randomized double-blind placebo-controlled trial of marimastat in patients with small cell lung cancer (SCLC) following response to first-line chemotherapy: an NCIC-CTG and EORTC Study","volume":"20","author":"Shepherd","year":"2001","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2005.12.020_bib31","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1023\/A:1025819214508","article-title":"Matrix metalloproteinases in colorectal cancer: is it worth talking about?","volume":"23","author":"Wagenaar-Miller","year":"2004","journal-title":"Cancer Metastasis Rev."},{"issue":"13","key":"10.1016\/j.ygyno.2005.12.020_bib32","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2003.07.013","article-title":"Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group Trial","volume":"21","author":"Markman","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 6","key":"10.1016\/j.ygyno.2005.12.020_bib33","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0959-8049(01)80555-4","article-title":"Randomized phase II study of BMS-275291 versus placebo in patients with stage IIIB or IV non-small cell lung cancer receiving paclitaxel plus carboplatin. National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) BR.18","volume":"37","author":"Douillard","year":"2001","journal-title":"Eur. J. Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825805011224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825805011224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T09:57:20Z","timestamp":1683367040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825805011224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["S0090825805011224"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2005.12.020","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}